Validation of patient-facing digital tool risk stratification of those at risk for hereditary cancer syndrome: The CARE program accurately identifies high risk individuals
Take home points:
The purpose of this study was to assess the analytic validity for the CARE platform by determining the accuracy of the digital tool’s execution and interpretation of NCCN guidelines® as compared to certified genetic counselor’s (CGC) interpretation of the same guidelines.
The CARE program’s analytic validity was 99.5% (398/400) for identifying individuals who met NCCN® genetic testing criteria.
The CARE program accurately identifies individuals who meet NCCN® testing criteria to aid in risk stratification.
Title: Validation of patient-facing digital tool risk stratification of those at risk for hereditary cancer syndrome: The CARE program accurately identifies high risk individuals